Biophytis S.A.
Research Biophytis S.A. (6XB3) on Bullrun: market cap EUR 13.77K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6XB3
- ExchangeF
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 13.77K
- Financial periodFY2024
- Free cash flow-EUR 8.64M
Valuation Snapshot
latest market cap is EUR 13.77K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | n/a | n/a | -EUR 8.64M | n/a | -2 | EUR 78.00K | EUR 6.61M | -EUR 9.67M |
| FY2023 | EUR 0 | -EUR 17.03M | -EUR 13.09M | n/a | -12.54 | EUR 5.57M | EUR 6.08M | -EUR 3.86M |
| FY2022 | EUR 0 | -EUR 24.22M | -EUR 19.13M | n/a | -55.4 | EUR 11.05M | EUR 4.37M | -EUR 1.88M |
| FY2021 | EUR 0 | -EUR 31.16M | -EUR 24.14M | n/a | -104 | EUR 23.93M | EUR 12.98M | EUR 5.84M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-17 | EUR 13.77K | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Biophytis S.A.'s market cap?
Biophytis S.A.'s market capitalization is EUR 13.77K.
What does Biophytis S.A. do?
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD.